Compare Futu Holdings Ltd (FUTU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Futu Holdings Ltd trades at $98.82 (market cap $13.94B), while State Street SPDR S&P Biotech ETF trades at $154.32. The key difference: Futu Holdings Ltd pays a 2.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Futu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| FUTU | XBI | |
|---|---|---|
Market Cap | $13.94B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $199.04 | $164.28 |
52-Week Low | $89.76 | $85.16 |
Enterprise Value | $13.79B | — |
Dividend Yield | 2.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUTU Holdings trades at $98.13, up 1.85% with a bullish technical signal despite mixed earnings. The company shows strong fundamentals with 2025 revenue of $22.85B and net income of $11.34B, supported by robust profitability margins. However, recent quarterly earnings misses and ongoing securities class action lawsuits create significant headwinds.
While valuation metrics appear reasonable with P/E of 10.98 and analyst consensus leaning bullish (58% buy ratings), investors face substantial legal and regulatory risks. The stock's near-term trajectory will depend on Q2 2026 earnings results and resolution of multiple class action lawsuits alleging securities fraud violations.
XBI trades at $155.19, down 0.23% on the day, with a bullish technical signal from moving averages. Recent news highlights strong biotech sector momentum, with the ETF gaining nearly 17% in a month (24/7 Wall Street, 2026-07-06). Analyst consensus is neutral with a single hold rating, while technical indicators show a neutral RSI and mixed ADX signals. Support is seen near $153, with resistance at $157.
The outlook for XBI is supported by sector strength and M&A activity, but high volatility and a neutral analyst stance suggest cautious optimism. Key risks include regulatory uncertainty and macroeconomic pressures, requiring careful risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
